Gilead Sciences, Merdad Parsey
Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company works to identify a successor, Dr. Parsey will continue as Chief Medical Officer until the first quarter of 2025 and support this transition over the next several months.
21h
Gilead Sciences, Inc. ( NASDAQ:GILD ) shareholders should be happy to see the share price up 15% in the last month.
The last few months have been difficult for Gilead, with several late-stage failures and development discontinuations. Amid ...
As Gilead hunts for a successor, Parsey will continue to serve as chief medical officer until the first quarter of 2025.
Gilead Sciences' chief medical officer, Merdad Parsey, will leave the company in early 2025, becoming the latest in a ...
The stock's fall snapped a four-day winning streak.
Zacks.com on MSN12d
Gilead (GILD) Loses 17.6% YTD: How Should You Play the Stock?Biotech giant Gilead Sciences, Inc. GILD, a leader in HIV drugs, is having a tough run as recent pipeline setbacks ...
TipRanks on MSN11d
Gilead Stock: Is this the Time to Go Long?Shares of biopharmaceutical giant Gilead Sciences (NASDAQ:GILD) have dropped nearly 20% over the past six months. In April, ...
Merdad Parsey joined Gilead as its chief medical officer in 2019 and has helped lead the company’s expansion into oncology, with mixed success.
COMPASS is Gilead’s 10 year, $100 million-plus commitment to address HIV in the U.S. South. Haddock showed off the check to ...
Gilead Sciences will announce data from several ongoing trials in human immunodeficiency virus (HIV) and acquired immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback